文献速递血栓与止血

因子VIIa与EPCR相互作用调节血友病治疗中rFVIIa的止血效应:作用机制

Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: Mode of its action.
PubMed 文献 · Blood Adv · 2017-01-01

本研究在小鼠血友病模型中探讨FVIIa与内皮细胞蛋白C受体(EPCR)结合增强重组因子VIIa(rFVIIa)止血效应的机制。活性位点抑制的FVIIa能结合EPCR但不能激活因子X,可降低纠正出血所需的rFVIIa浓度;EPCR过表达小鼠需更高剂量rFVIIa恢复止血;EPCR缺陷小鼠中FVIII抗体仅引起轻度出血,低剂量rFVIIa即可完全纠正。治疗浓度rFVIIa使EPCR过表达小鼠血浆蛋白C水平升高,提示rFVIIa置换EPCR结合的蛋白C。EPCR水平不影响rFVIIa血浆生物利用度。

要点

  • 活性位点抑制的FVIIa可降低小鼠血友病模型纠正出血所需的rFVIIa浓度。
  • EPCR过表达血友病小鼠较EPCR正常水平小鼠需更高剂量rFVIIa恢复止血。
  • 治疗浓度rFVIIa使EPCR过表达小鼠血浆蛋白C升高,提示置换EPCR结合的蛋白C。

核心结论

  • EPCR水平影响rFVIIa治疗血友病的止血效应。
  • FVIIa与EPCR结合通过置换抗凝蛋白C、下调活化蛋白C生成而贡献止血效应,而非EPCR-FVIIa直接激活因子X。

研究设计与样本

  • 小鼠血友病模型研究。

主要发现

  • 活性位点抑制的FVIIa能结合EPCR但不能激活因子X,降低纠正隐静脉损伤后出血所需的rFVIIa浓度。
  • EPCR过表达血友病小鼠较EPCR正常水平血友病小鼠需更高剂量rFVIIa恢复止血。
  • EPCR缺陷小鼠给予FVIII抗体仅引起轻度血友病出血,低剂量rFVIIa完全纠正。
  • 治疗浓度rFVIIa使EPCR过表达小鼠血浆蛋白C水平升高,提示rFVIIa置换EPCR结合的蛋白C。
  • EPCR水平未显著改变rFVIIa血浆生物利用度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent studies established that clotting factor VIIa (FVIIa) binds endothelial cell protein C receptor (EPCR). It has been speculated that FVIIa interaction with EPCR might augment the hemostatic effect of rFVIIa in therapeutic conditions. The present study is carried out to investigate the mechanism by which FVIIa interaction with EPCR contributes to the hemostatic effect of rFVIIa in hemophilia therapy. Active-site inhibited FVIIa, which is capable of binding to EPCR but has no ability to activate factor X, reduced the concentration of rFVIIa required to correct the bleeding following the saphenous vein injury in mouse hemophilia model systems. Higher doses of rFVIIa were required to restore hemostasis in EPCR overexpressing hemophilia mice compared to hemophilia mice expressing normal levels of EPCR. Administration of FVIII antibody induced only mild hemophilic bleeding in EPCR-deficient mice, which was corrected completely with a low dose of rFVIIa. Administration of therapeutic concentrations of rFVIIa increased plasma protein C levels in EPCR overexpressing mice, indicating the displacement of protein C from EPCR by rFVIIa. EPCR levels did not significantly alter the bioavailability of rFVIIa in plasma. Overall, our data indicate that EPCR levels influence the hemostatic effect of rFVIIa in treating hemophilia. Our present findings suggest that FVIIa displacement of anticoagulant protein C from EPCR that results in down-regulation of activated protein C generation and not the direct effect of EPCR-FVIIa on FX activation is the mechanism by which FVIIa interaction with EPCR contributes to the hemostatic effect of rFVIIa in hemophilia therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Keshava S, Sundaram J, Rajulapati A, et al. Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: Mode of its action. Blood Adv. 2017. PMID: 28932824. doi:10.1182/bloodadvances.2016004143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。